Drug Profile
Research programme: autoimmune disorders - Daiichi Sankyo/Quark Biotech
Latest Information Update: 12 Mar 2007
Price :
$50
*
At a glance
- Originator Quark Biotech
- Class
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 12 Mar 2007 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 26 Nov 2001 This programme is still in active development